Anti-AIDS agents.: 37.: Synthesis and structure-activity relationships of (3′R,4′R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents

被引:164
作者
Xie, L
Takeuchi, Y
Cosentino, LM
Lee, KH [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Nat Prod Lab, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA
[2] Biotech Res Labs, Gaithersburg, MD 20877 USA
关键词
D O I
10.1021/jm9900624
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To explore the structural requirements of (+)-cis-khellactone derivatives as novel anti-HIV agents, 24 monosubstituted 3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) derivatives were synthesized asymmetrically. These compounds included 4 isomeric monomethoxy analogues (3-6), 4 isomeric monomethyl analogues (7-10), 4 4-alkyl/aryl-substituted analogues (11-14), and 12 4-methyl-(+)-cis-khellactone derivatives (15-26) with varying 3',4'-substituents. These (+)-cis-khellactone derivatives were screened against HIV-1 replication in acutely infected H9 lymphocytes. The results demonstrated that the (3'R,4'R)-(+)-cis-khellactone skeleton, two (S)-(-)-camphanoyl groups at the 3'- and 4'-positions, and a methyl group on the coumarin ring, except at the 6-position, were optimal structural moieties for anti-HIV activity. 3-Methyl- (7), 4-methyl- (8), and 5-methyl- (9) 3',4'-di-O(S)-camphanoyl-(3'R,4'R)-(+)-cis-khellactone showed EC50 and therapeutic index values of <5.25 x 10(-5) mu M and >2.15 x 10(6), respectively, in H9 lymphocytes, which are much better than those of DCK and AZT in the same assay. Furthermore, 8 and 9 also showed potent inhibitory activity against HIV-1 replication in the CEM-SS cell line, and most monosubstituted DCK analogues were less toxic than DCK in both assays.
引用
收藏
页码:2662 / 2672
页数:11
相关论文
共 35 条
[1]  
AHLUMALIA YK, 1977, INDIAN J CHEM B, V15, P945
[2]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[3]   Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug [J].
Borman, AM ;
Paulous, S ;
Clavel, F .
JOURNAL OF GENERAL VIROLOGY, 1996, 77 :419-426
[4]   IMPROVED ENANTIOSELECTIVITY IN ASYMMETRIC DIHYDROXYLATIONS OF TERMINAL OLEFINS USING PYRIMIDINE LIGANDS [J].
CRISPINO, GA ;
JEONG, KS ;
KOLB, HC ;
WANG, ZM ;
XU, DQ ;
SHARPLESS, KB .
JOURNAL OF ORGANIC CHEMISTRY, 1993, 58 (15) :3785-3786
[5]   TOWARD IMPROVED ANTI-HIV CHEMOTHERAPY - THERAPEUTIC STRATEGIES FOR INTERVENTION WITH HIV-INFECTIONS [J].
DECLERCQ, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (14) :2491-2517
[6]   FUTURE TREATMENT STRATEGIES IN HIV-INFECTION [J].
DORMONT, J .
AIDS, 1994, 8 :S31-S33
[7]   GENERATION AND CHARACTERIZATION OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) MUTANT RESISTANT TO AN HIV-1 PROTEASE INHIBITOR [J].
ELFARRASH, MA ;
KURODA, MJ ;
KITAZAKI, T ;
MASUDA, T ;
KATO, K ;
HATANAKA, M ;
HARADA, S .
JOURNAL OF VIROLOGY, 1994, 68 (01) :233-239
[8]   DEOXYGENATION OF ALDEHYDES AND KETONES WITH SODIUM CYANOBOROHYDRIDE [J].
ELLIGER, CA .
SYNTHETIC COMMUNICATIONS, 1985, 15 (14) :1315-1324
[9]  
FALL Y, 1995, HETEROCYCLES, V41, P647
[10]   ISOLATION OF HUMAN T-CELL LEUKEMIA-VIRUS IN ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
GALLO, RC ;
SARIN, PS ;
GELMANN, EP ;
ROBERTGUROFF, M ;
RICHARDSON, E ;
KALYANARAMAN, VS ;
MANN, D ;
SIDHU, GD ;
STAHL, RE ;
ZOLLAPAZNER, S ;
LEIBOWITCH, J ;
POPOVIC, M .
SCIENCE, 1983, 220 (4599) :865-867